Meeting
2012 Genitourinary Cancers Symposium
Randomized study on the effect of zoledronic acid treatment for prostate cancer with bone metastasis during initial combined androgen blockade.
Authors
Satoru Ueno
Department of Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Satoru Ueno , Atsushi Mizokami , Mikio Namiki , Takashi Fukagai , Naohiro Fujimoto , Hitoshi Ooka , Yukihiro Kondo , Gaku Arai , Hisamitsu Ide , Kazuyoshi Kataoka , Kohei Kawaguchi , Masayoshi Shimamura , Matsuo Orito , Takeyuki Ishida , Daisuke Ikeda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 48)
DOI
10.1200/jco.2012.30.5_suppl.48
Abstract #
48
Poster Bd #
C14
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer (Zabton-PC) study.
First Author: Satoru Ueno
Poster
2011 ASCO Annual Meeting
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain.
First Author: N. D. Shore
Poster
2013 ASCO Annual Meeting
Use of serum markers in prediction of survival in the trapeze factorial trial evaluating docetaxel with zoledronic acid, strontium-89, or both in castrate-refractory prostate cancer (CRPC) metastatic to bone.
First Author: Vivek K Wadhwa
Poster
2013 Genitourinary Cancers Symposium
Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).
First Author: Matthew Raymond Smith